Covered recipient · General Payments record
MAEN HUSSEIN
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$15,190.80
174 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,864.06 | 5 |
| Consulting Fee | $3,500.00 | 3 |
| Food and Beverage | $2,814.82 | 165 |
| Education | $11.92 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MAEN HUSSEIN
NPI 1356332506 · CMS profile ID 333099
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
TAVARES, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1356332506?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MAEN HUSSEIN, NPI 1356332506, CMS profile ID 333099. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356332506?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). MAEN HUSSEIN, NPI 1356332506, CMS profile ID 333099. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356332506?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- MAEN HUSSEIN, NPI 1356332506, CMS profile ID 333099, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1356332506?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
174 matching records · $15,190.80 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 174.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $22.43 | 09/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788145429 | CMS |
| Rigel Pharmaceuticals, Inc. | $19.59 | 09/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 854327339 | CMS |
| Daiichi Sankyo Inc. | $34.99 | 09/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836322463 | CMS |
| GENZYME CORPORATION | $13.89 | 09/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843580883 | CMS |
| JAZZ PHARMACEUTICALS INC. | $11.69 | 08/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845555923 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.20 | 08/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834349163 | CMS |
| Eisai Inc. | $13.83 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 817983471 | CMS |
| PFIZER INC. | $19.26 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832817499 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.53 | 08/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783603465 | CMS |
| Genentech USA, Inc. | $14.65 | 08/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835943533 | CMS |
| Amgen Inc. | $16.42 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825568335 | CMS |
| Eisai Inc. | $21.22 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 817975615 | CMS |
| Genentech USA, Inc. | $15.47 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835943545 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.90 | 08/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834326301 | CMS |
| Seagen Inc. | $15.07 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832177435 | CMS |
| Ipsen Biopharmaceuticals, Inc | $14.93 | 08/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 841906309 | CMS |
| Karyopharm Therapeutics Inc. | $12.24 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845786815 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $12.96 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781011241 | CMS |
| Seagen Inc. | $19.71 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832177433 | CMS |
| TerSera Therapeutics LLC | $40.51 | 08/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851045171 | CMS |
| Eisai Inc. | $19.31 | 08/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 817973863 | CMS |
| Incyte Corporation | $16.90 | 08/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835537085 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.39 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834338133 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.77 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834340019 | CMS |
| JAZZ PHARMACEUTICALS INC. | $14.18 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845549765 | CMS |
| GlaxoSmithKline, LLC. | $13.06 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802018261 | CMS |
| Eisai Inc. | $19.53 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 817969421 | CMS |
| Foundation Medicine, Inc. | $17.35 | 07/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799850987 | CMS |
| Lilly USA, LLC | $17.42 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818584927 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.90 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834317673 | CMS |
| Amgen Inc. | $25.16 | 07/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826384295 | CMS |
| Boehringer Ingelheim International GmbH | $2,094.01 | 07/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 822295127 | CMS |
| Genentech USA, Inc. | $15.11 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835943529 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $11.30 | 07/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781011239 | CMS |
| GlaxoSmithKline, LLC. | $19.26 | 07/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802523139 | CMS |
| Janssen Biotech, Inc. | $20.33 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788145443 | CMS |
| Blueprint Medicines Corporation | $15.81 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848928131 | CMS |
| GENZYME CORPORATION | $20.30 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843580849 | CMS |
| Heron Therapeutics, Inc. | $17.35 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781449779 | CMS |
| Janssen Biotech, Inc. | $17.18 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788145445 | CMS |
| Seagen Inc. | $20.25 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832177393 | CMS |
| Janssen Biotech, Inc. | $19.89 | 06/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788145439 | CMS |
| Astellas Pharma US Inc | $16.76 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821374745 | CMS |
| Amgen Inc. | $5.81 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826384291 | CMS |
| Amgen Inc. | $14.86 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826384293 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.50 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763534976 | CMS |
| PFIZER INC. | $19.75 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832635273 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.49 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834345963 | CMS |
| Gilead Sciences, Inc. | $12.57 | 06/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848212819 | CMS |
| Global Blood Therapeutics, Inc. | $12.98 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835340015 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $4,360.00 | 5 |
| PY2025 | Principal investigator | $340,884.19 | 528 |
| PY2024 | Recipient | $4,800.00 | 4 |
| PY2024 | Principal investigator | $377,134.00 | 130 |
| PY2023 | Recipient | $3,200.00 | 1 |
| PY2023 | Principal investigator | $1,844,755.17 | 186 |
| PY2022 | Recipient | $5,052.00 | 3 |
| PY2022 | Principal investigator | $1,596,086.63 | 191 |
| PY2021 | Recipient | $1,949.97 | 2 |
| PY2021 | Principal investigator | $1,569,652.65 | 275 |
| PY2020 | Recipient | $4,659.12 | 1 |
| PY2020 | Principal investigator | $2,574,107.72 | 208 |
| PY2019 | Recipient | $1,031.25 | 1 |
| PY2019 | Principal investigator | $9,876,266.37 | 161 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
533 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644987 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644993 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645003 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645005 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645007 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645009 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645011 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645013 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645015 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645017 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645019 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645023 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645025 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645027 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645029 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645031 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645033 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645035 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645037 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645041 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645043 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645045 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645047 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645049 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645053 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645057 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645065 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645067 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645069 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645071 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645073 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645075 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645077 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645079 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645081 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645083 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645085 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645087 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645089 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645091 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645093 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645095 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645097 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644855 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644857 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644859 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644861 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644935 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644941 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644967 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644969 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644973 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220644977 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $796.89 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB IIIA non small cell lung carcinoma following complete tumour resection with or without adjuvant chemotherapy | No dispute reported | 06/30/2026 | 1185538725 |
| Principal investigator 1 | Genentech, Inc. | $83.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC | No dispute reported | 06/30/2026 | 1211652446 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 10/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC | No dispute reported | 06/30/2026 | 1211652391 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $75.00 | 10/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946915 |
| Principal investigator 1 | BeOne Medicines Ltd. | $300.00 | 10/21/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190333171 |
| Recipient | PFIZER INC. | $940.00 | 10/19/2025 | Covered Recipient Physician | BINIMETINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228804052 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645703 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645707 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645709 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645711 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645713 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645715 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645717 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645719 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645725 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645727 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645729 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645731 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645737 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645739 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645743 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645749 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645751 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645755 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645759 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645765 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645767 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645769 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645775 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645777 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645781 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645785 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645793 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645795 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645797 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645799 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645801 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645805 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645807 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645809 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645811 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645813 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645815 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645819 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,950.00 | 09/16/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190333164 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645587 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645589 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645591 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645593 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645595 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645599 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645601 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645603 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645607 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645609 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645611 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645613 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645615 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645617 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645619 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645621 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645623 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645625 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645627 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645629 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645631 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645633 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645635 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645637 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645639 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645641 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645643 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645645 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645647 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645649 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645651 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645653 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645655 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645657 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645659 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645661 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645663 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645665 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645667 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645669 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645671 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645673 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645675 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645677 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645679 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645681 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645683 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645685 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645687 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645689 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645691 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645693 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645695 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645697 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645699 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645701 |
| Principal investigator 1 | ARRAY BIOPHARMA INC | $1,729.00 | 08/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228833500 |
| Recipient | PFIZER INC. | $1,820.00 | 08/22/2025 | Covered Recipient Physician | DACOMITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228804047 |
| Principal investigator 1 | Genentech, Inc. | $506.70 | 08/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC | No dispute reported | 06/30/2026 | 1211651669 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 08/12/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190333159 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645459 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645465 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645469 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645473 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645489 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645507 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645513 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645531 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645543 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645547 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645557 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645565 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645567 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645575 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645581 |
| Principal investigator 1 | Genentech, Inc. | $354.00 | 07/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 1LM SCLC Tecentriq Lurbinectedin | No dispute reported | 06/30/2026 | 1211649164 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $156.25 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946911 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $375.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946913 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 07/15/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190333168 |
| Principal investigator 1 | Genentech, Inc. | $9,876.00 | 07/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | No dispute reported | 06/30/2026 | 1211649177 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645359 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645361 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645363 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645365 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645367 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645369 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645371 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645373 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645375 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645377 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645379 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645381 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645383 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645385 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645387 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645389 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645391 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645393 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645395 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645397 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645399 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645401 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645403 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645405 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645407 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645411 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645415 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645417 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645421 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645423 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645425 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645427 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645429 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645431 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645433 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645435 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645437 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645441 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645443 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645445 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645447 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645451 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645453 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645455 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645457 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 06/17/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190331509 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 06/10/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190331507 |
| Principal investigator 1 | BeOne Medicines Ltd. | $5,100.00 | 06/10/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190331511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645227 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645229 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645231 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645233 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645235 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645243 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645245 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645247 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645249 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645251 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645253 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645255 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645257 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645259 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645261 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645263 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645265 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645267 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645269 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645271 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645273 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645275 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645277 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $262.50 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645279 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,704.63 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645281 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645283 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645285 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645287 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645289 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645293 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645295 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645297 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645299 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645301 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645303 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $975.00 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645305 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $750.00 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645307 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645309 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645311 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645313 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645315 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645317 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645319 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645321 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645323 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645325 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645327 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645329 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645331 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645333 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645335 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645337 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645339 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645341 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645343 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645345 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645347 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645349 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645351 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645353 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645355 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645357 |
| Recipient | PFIZER INC. | $940.00 | 05/31/2025 | Covered Recipient Physician | ENCORAFENIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228839003 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | ENCORAFENIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838363 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,507.50 | 05/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185538727 |
| Principal investigator 1 | Genentech, Inc. | $91,875.00 | 05/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC | No dispute reported | 06/30/2026 | 1211651508 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $77,621.00 | 05/06/2025 | Non-covered Recipient Entity Florida Cancer Specialists - North | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235997337 |
| Principal investigator 1 | BeiGene, Ltd. | $8,907.50 | 05/05/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190323316 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,418.61 | 04/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185538723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645171 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645173 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645175 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645177 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645179 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645181 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645183 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645185 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645187 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645189 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645191 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645193 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645195 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645197 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645199 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645201 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645203 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645205 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645207 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645209 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645211 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645213 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645215 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645217 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645219 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645221 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645223 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645225 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 04/22/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190323314 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $19,405.48 | 04/17/2025 | Non-covered Recipient Entity SARAH CANNON CANCER INSTITUTE AT HDH | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176545039 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $2,514.00 | 04/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530655 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 04/08/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190323318 |
| Principal investigator 1 | Genentech, Inc. | $125.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC | No dispute reported | 06/30/2026 | 1211651222 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645105 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645107 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645109 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645111 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645113 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645115 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645117 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645119 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645121 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645125 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645129 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645131 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645133 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645135 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645137 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645139 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645143 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645145 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645147 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645149 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645151 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645153 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645157 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645159 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645161 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645165 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645167 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute North Region Research Office | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220645169 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $13,142.25 | 03/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530651 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $10,948.75 | 03/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946909 |
| Principal investigator 1 | AstraZeneca UK Limited | $114.29 | 02/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase II Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer ORION | No dispute reported | 06/30/2026 | 1185538721 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $338.62 | 02/25/2025 | Non-covered Recipient Entity Florida Cancer Specialists - North | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235997339 |
| Principal investigator 1 | Genentech, Inc. | $4,000.00 | 02/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC | No dispute reported | 06/30/2026 | 1211650637 |
| Principal investigator 1 | Genentech, Inc. | $140.40 | 02/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC | No dispute reported | 06/30/2026 | 1211650812 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $31.00 | 02/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946903 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $31.00 | 02/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946905 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $31.00 | 02/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946907 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $3,000.00 | 02/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946901 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 02/11/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190324798 |
| Principal investigator 1 | ARRAY BIOPHARMA INC | $650.00 | 02/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228853549 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $2,500.00 | 02/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946899 |
| Recipient | PFIZER INC. | $330.00 | 01/24/2025 | Covered Recipient Physician | BINIMETINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228839036 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 01/21/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | No dispute reported | 06/30/2026 | 1190324796 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,525.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185538729 |